Mesothelioma: VS-5584 Received Orphan Drug Designation

Verastem. Inc, a pharmaceutical company focused on the discovery and development of drugs directed against cancer stem cells, recently announced that VS-5584, oral inhibitor of focal adhesion kinase (FAK), has received orphan drug designation from the US Food and Drug Administration, for use in the treatment of mesothelioma.

It is an important regulatory milestone for Verastem that will facilitate the global development of the VS-5584, and that will help improve the treatment options available for patients suffering from this type of very aggressive cancer, said Robert Forrester, President Verastem.

Verastem has recently initiated a Phase 1 clinical study in order to evaluate the synergistic activity in combination with VS-5584 VS-6063, in patients with progressive or relapsed malignant pleural mesothelioma.

Moreover VS-5584 is subjected to a phase 1 further study to evaluate the use against advanced solid tumors, such as mesothelioma, in patients who have previously shown good tolerance to the drug.

Comments

General Information about Malignant Mesothelioma

Malignant mesothelioma is a disease in which malignant (cancerous) cells form in the lining of the chest or abdomen. Malignant mesothelioma is a disease in which malignant (cancer) cells are found in the pleura (the thin layer of tissue that lines the chest cavity and covers the lungs) or the peritoneum (the thin layer of tissue that lines the abdomen and covers most of the organs of the abdomen). Malignant mesothelioma can form in the heart or testicles, but this is not common Exposure to asbestos can influence the risk of malignant mesothelioma. Anything that increases the risk of getting a disease is called a risk factor. Having a risk factor does not mean you are going to have cancer; Having no risk factors does not mean you will not have cancer. Talk to your doctor if you think you may be at risk. Most people with malignant mesothelioma have worked or lived in places where they inhaled or swallowed asbestos. After exposure to asbestos, it usually takes a lon

Mesothelioma Pathology

Mesothelioma can be divided into types of localized and diffuse pathology, but the former is extremely rare. When making a diagnosis of mesothelioma, it is important to confirm the location of the tumor and the specific raw results before histological examination. Mesothelioma can be categorized histologically as epithelioid type, sarcomatoid type, biphasic type, desmoplastic type, among others. It can take many forms; consequently, there are many diseases to be differentiated when the pathology diagnosis of mesothelioma is based on histological analyzes. Immunohistochemical stains are useful for diagnosis, but the right combination of antibodies as positive or negative markers should be selected and a full evaluation of the results of staining is necessary. The accuracy of pathological diagnosis is very important for patients because they can receive official compensation or relief when the diagnosis of mesothelioma disease is confirmed. Under current conditions, clini

Diagnosis and Staging of Mesothelioma

Mesothelioma is a rare and very aggressive tumor that affects the pleura, and its main cause is exposure to asbestos, a mineral used in construction whose use was banned four decades ago. Diagnosis and staging of mesothelioma Because the symptoms of this tumor are very unspecific, findings of suspected mesothelioma appear radiology, after checking history of exposure to asbestos. The various radiological tests: CT or MRI are useful for the extension study or to determine resectability (operability) or injury. PET is superior to CT setting distant disease, but it has limitations in the locoregional staging. Obtaining a sample for pathological diagnosis of mesothelioma can be thoracentesis (obtaining pleural fluid) for subsequent cytological, but the profitability of this test is not more than 33%. The pleural biopsy to obtain a tissue cylinder can be done blind (50% yield), or open by thoracoscopy (VATS), or thoracotomy, reaching up to 95% return; also reports t

Mesothelioma Pathology Outlines

Search This Blog